Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 19/20 | 1.00 |
| ▸ | WNT3A | P56704 | 13/20 | 0.74 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15979891 | 0.92 | CTNNB1 (0.85) | CTNNB1WNT3APKM | |
| SCHEMBL653271 | 0.90 | CTNNB1 (1.00) | CTNNB1WNT3APKM | |
| SCHEMBL15969289 | 0.85 | CTNNB1 (1.00) | CTNNB1WNT3APKMTSHR | |
| SCHEMBL15979799 | 0.84 | CTNNB1 (0.77) | CTNNB1WNT3A | |
| SCHEMBL15979765 | 0.84 | CTNNB1 (0.72) | CTNNB1WNT3A | |
| SCHEMBL15979790 | 0.84 | CTNNB1 (0.72) | CTNNB1WNT3A | |
| SCHEMBL15979753 | 0.83 | CTNNB1 (0.72) | CTNNB1WNT3A | |
| SCHEMBL15969172 | 0.83 | CTNNB1 (1.00) | CTNNB1WNT3APKMTSHR | |
| SCHEMBL30441632 | 0.83 | CTNNB1 (1.00) | CTNNB1WNT3APKMTSHR | |
| SCHEMBL15969344 | 0.83 | CTNNB1 (1.00) | CTNNB1WNT3APKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839679-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11839679-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230053726-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2023-02-23 | — | — | US | disclosed |
| US-20220087917-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2022-03-24 | — | — | US | disclosed |
| EP-3915367-A1 | DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS | BioSplice Therapeutics, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3915367-A1 | DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS | BioSplice Therapeutics, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| US-20210353604-A1 | ß- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ ß -CATENIN SIGNALING PATHWAY ACTIVATORS | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2021-11-18 | — | — | US | disclosed |
| US-20210353604-A1 | ß- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ ß -CATENIN SIGNALING PATHWAY ACTIVATORS | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2021-11-18 | — | — | US | disclosed |
| US-8629176-B1 | β- and γ-diketones and γ-hydroxyketones as WNT/ β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629176-B1 | β- and γ-diketones and γ-hydroxyketones as WNT/ β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2014-01-14 | — | — | US | disclosed |
| US-20140005228-A1 | B- AND Y -DIKETONES AND Y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS | SAMUMED, LLC (US) | 2014-01-02 | — | — | US | disclosed |
| US-8609717-B2 | β- and γ-diketones and γ-hydroxyketones as WNT/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2013-12-17 | — | — | US | disclosed |
| EP-2605652-A1 | DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS | Samumed, LLC (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012024404-A1 | DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS | WINTHERIX, LLC (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012024404-A1 | DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS | WINTHERIX, LLC (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046320-A1 | BETA- AND GAMMA-DIKETONES AND GAMMA-HYDROXYKETONES AS WNT/BETA-CATENIN SIGNALING PATHWAY ACTIVATORS | WINTHERIX, LLC (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046320-A1 | BETA- AND GAMMA-DIKETONES AND GAMMA-HYDROXYKETONES AS WNT/BETA-CATENIN SIGNALING PATHWAY ACTIVATORS | WINTHERIX, LLC (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046320-A1 | BETA- AND GAMMA-DIKETONES AND GAMMA-HYDROXYKETONES AS WNT/BETA-CATENIN SIGNALING PATHWAY ACTIVATORS | WINTHERIX, LLC (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220087917-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | GLA, DGKG, DGKA | CTNNB1 1789/4885WNT3A 1618/4885PKM 255/4885 |
| US-20210353604-A1 | ß- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ ß -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | CTNNB1 6/4885WNT3A 4/4885PKM 1034/4885 |
| US-20140005228-A1 | B- AND Y -DIKETONES AND Y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3B, WNT3A, GSK3A | CTNNB1 6/4885WNT3A 2/4885PKM 1429/4885 |
| US-11839679-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | DGKG, DGKA, DNER | CTNNB1 1475/4885WNT3A 1983/4885PKM 298/4885 |
| US-20230053726-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | CTNNB1 6/4885WNT3A 4/4885PKM 1148/4885 |
| US-20120046320-A1 | BETA- AND GAMMA-DIKETONES AND GAMMA-HYDROXYKETONES AS WNT/BETA-CATENIN SIGNALING PATHWAY ACTIVATORS | WNT1, CTNNA1, WNT3A | CTNNB1 6/4885WNT3A 3/4885PKM 1441/4885 |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | CTNNB1 5/4885WNT3A 4/4885PKM 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.